Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17083)	3/10/1998 2:20:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Henry, "The IL-2 fusion protein is for CTCL (same disease targeted by Targretin)." I'm not sure why LGND would want two drugs targeting the same disease. Are they just 'buying' a possible competitor? Regards, Walter

To: Henry Niman who wrote (17083)	3/10/1998 2:31:00 PM
From: tuck	Read Replies (1) \| Respond to of 32384

Henry and RB, See? I told you so! No, really, I appreciate your thoughts on this. Kind of funny how hard it is not to misunderstand/misrepresent even when we're trying to communicate well and presumably like each other. OK, then. So it's a serum. I am pretty sure the word "estrogen" was in front of serum when I was told of this. Does that make any sense, or are we treading again on the path of confusion? You seem very locked in on DAB389IL-2. Does it have to do with estrogen or am I talking of something much different from the prevailing speculation? I take it Seragen and Lilly have some relationship I am unaware of. I for one am ignoring any post involving TonyT. I just don't have the time. Regards, Tuck